ArticleFrontiers in immunology2026
Pathological complete response following immunotherapy in dMMR/MSI-H ascending colon primary squamous cell carcinoma: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary colon squamous cell carcinoma (SCC) is an extremely rare malignancy and associated with a poor prognosis. This case report describes a patient with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) ascending colon SCC, who was treated at our institution. After receiving four cycles of programmed cell death -1 (PD-1) blockade monotherapy, the tumor exhibited significant regression, and pathological complete response (pCR) was achieved following surgical resection. This case demonstrates that Anti-PD-1 therapy can induce clinically meaningful tumor regression even in this rare colon SCC subtype, suggesting a potential treatment strategy for dMMR/MSI-H colon SCC. These findings may provide valuable insights for clinicians managing similar cases. However, the feasibility and safety of immunotherapy in dMMR/MSI-H primary colon SCC require further validation through additional clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.